ART Launches in-Vivo Optical Molecular Imaging Device for Drug Development

ART Advanced Research Technologies Inc. has announced the commercial launch of a new version of its optical molecular imaging system, called eXplore Optix MX2 which is designed to offer the high sensitivity and unique optical molecular imaging features.

The MX2 is designed to further improve workflow efficiency while providing a richer data set through advanced data collection and analysis solutions.

“As customers in the drug discovery and development process continue to demand tools for a deeper level of analysis, we are providing them with an optical imaging system which sets new benchmarks for sensitivity, while ensuring reliability and performance for applications requiring longitudinal studies,” said Sebastien Gignac, President and CEO of ART.

“Today, we are more capable than ever of reducing cost and time to market for scientists by combining leading edge technology with flexible software solutions. We can help advance discovery faster through the adoption of ART’s time-domain technology among industrial and academic researchers in the preclinical phases of drug development,” said Gignac.

According to ART, eXplore Optix MX2 is the most sensitive optical imager commercially available on the market, based on time-domain technology which allows measurement of the light’s time of arrival, allowing for detection of lower concentrations of signals deeper inside the body.

The eXplore Optix MX2’s ability to recover fluorescence lifetime can be used to separate and quantify probe distributions depending on their respective biochemical environment. Also part of the MX2, is a new CT fusion software package allowing researchers to export the scan obtained using eXplore Optix MX2 in DICOM format, and fuse it with micro-CT for a full 3D anatomical reference.